【乳癌】治療三陰性乳癌(TNBC)新藥「LP-184」獲得進入1b/2期臨床IND 批准

 【乳癌】治療三陰性乳癌(TNBC)新藥「LP-184」獲得進入1b/2期臨床IND 批准

 文章出處  

Businesswire 

 

 原文標題  

Lantern Advances Drug Candidate LP-184 with IND Clearance for Phase 1b/2 Clinical Trial in Triple Negative Breast Cancer (TNBC) 

 

 Twitter  

https://x.com/aimedadviser/status/1919557773555323202 

 

 文章序號  

7902 

 

智醫科學－AI醫療技術、應用與市場動態

Copyright ©2025 智醫科學 MEDai.tw All rights reserved.

The content of this site is intended for healthcare and medical professionals.